Methods: We performed a cost-utility analysis (National Health Service (NHS) perspective) alongside the Building Blocks trial (over 2.5 y). The analysis was conducted in accordance with National Institute for Health and Clinical Excellence (NICE) reference case standards. Healthrelated quality of life was elicited from mothers using the EQ-5D-3L. Resource-use data were collected from self-reported questionnaires, Hospital Episode Statistics, general practitioner records and the central Department of Health FNP database. Costs and quality-adjusted life years (QALYs) were discounted at 3.5%. The base case analysis used an intention to treat approach on the imputed dataset using multiple imputation.
The Family Nurse Partnership (FNP) programme is an intensive preventive home visiting service with positive results compared to usual services for mothers and babies both in the United States and the Netherlands. [1] [2] [3] [4] It was introduced for first-time young mothers into NHS England by the Department of Health [5] [6] [7] in 2006. In October 2015, the FNP was transferred from NHS England to local authorities (LAs) and it is provided in approximately 125 different LAs in England.
The FNP programme was introduced to be an integral part of the progressive universalism approach recommended in the Healthy Child
Programme. The Healthy Child Programme is delivered by the family nurse rather than by health visitors for women who enrol onto the programme.
Given the lack of evidence on the benefits of the FNP programme in England, the Building Blocks (BB) trial was commissioned to evaluate the effectiveness and cost-effectiveness of the FNP intervention when delivered in a comprehensive publicly funded health care setting. The BB protocol has been published, 8 and all amendments were reviewed and approved by the Wales NHS Research Ethics Committee (09/ MRE09/08). The details of the trial design, outcomes, and clinical effectiveness are reported elsewhere. 9, 10 The results from the effectiveness analysis showed no statistically or clinically significant differ- This paper reports on the cost-effectiveness analysis conducted alongside the BB trial. This economic analysis also seeks to better understand a key example of an intervention that is routinely provided without clear evidence on whether it represents good value for money for the health system compared to comprehensive services, which in turn may help to guide disinvestment decisions that are unavoidable given the financial constraints within a publicly funded health care system.
| METHODS

| Overview
Individual patient data from the BB trial were used to perform a costutility analysis measuring health-related quality of life in terms of quality-adjusted life years (QALYs). The analysis was from the NHS and personal social services perspective and expressed in UK pounds sterling Grait Britain Pounds (2013 GBP). Costs and QALYs were discounted at a rate 11 of 3.5%. We used a regression approach on an intention-to-treat (ITT) basis. The base case analysis was conducted on the dataset generated by multiple imputation (MI) by chained equations. 12 Sensitivity analysis included complete case (CC) analysis to test the impact of excluding participants with missing data on the final results. All analyses and modelling were conducted in Stata 13.1 (StataCorp 2011, Texas).
The BB trial was a pragmatic, nonblinded, parallel-group, randomised controlled trial, which recruited within a community mid- 
| Health outcomes and QALYs
The primary outcome measure was QALYs, based on the EQ-5D-3LTM (EuroQoL Group Rotterdam, The Netherlands) reported by the women. The EQ-5D-3L has been used before in the UK setting within the context of a pregnant population, for example, in the economic evaluation conducted alongside the Early Labour Support and Assessment trial. 13 The EQ-5D-3L health states were valued using a UKbased social tariff. 14 The QALYs were calculated using the area under the curve method 15 and were adjusted for baseline utility. 
| Handling missing data
Complete case assessment excludes all participants with any missing or incomplete data. Excluding patients with missing data leads to loss of power and biasing of the results because of a reduced sample size. 19 The method we used to handle missing data was informed by the BB data. Incomplete data on costs and QALYs were imputed using MI with chained equations and predictive mean matching, which assumes that data are missing at random. [20] [21] [22] The same set of covariates as in the clinical effectiveness analysis was selected with stepwise regressions (eg, site, smoking status, language, and gestation). Rubin's rules were used to combine point and variance estimates across imputed datasets, allowing the estimation of difference in costs and QALYs between both groups. 23 
| Base-case analysis
The base-case analysis was conducted on the multiple imputed dataset and followed an ITT approach. For the base-case analysis, total costs constituted the cost of the FNP programme (nurse time used for home-based visits from the FNP nurse); GP and nurse visits (recorded in GP records), postnatal midwife and health visitor visits (self-reported by mothers); and hospital activity (HES records for inpatient admission, outpatient visits and A&E services).
The cost-effectiveness of the FNP programme was evaluated by comparing the mean differences in costs and effects in the 2 groups, using conventional rules and estimating the incremental costeffectiveness ratio as appropriate. 24 The mean differences in costs and QALYs were estimated using seemingly unrelated regression, 25 and their 95% confidence intervals (CIs) estimated using bias-corrected and accelerated bootstrap methods. Nonparametric bootstrapping 26 was used to transform the uncertainty around the trial estimates into the probability that the FNP intervention is cost-effective for thresholds used by the National Institute for Health and Care
Excellence (NICE) of £20 000 and £30 000 per QALY gained, 11 with cost-effectiveness acceptability curves (CEACs) used.
| Sensitivity analyses
Sensitivity analyses in the base case were conducted to test the robustness of the results using 5 scenarios: CC analysis according to ITT; MI removing midwife visits reported by mothers allocated to FNP (ie, to avoid double counting in case those visits were already included in the FNP IS dataset); MI including the limited data available for mothers that withdrew due to mandatory withdrawals (ie, if FNP were to be implemented, costs related to mandatory withdrawals would be covered by the NHS); MI using self-report data (ie, including resource use exclusively related to mothers, hence excluding resource Table 2 presents the proportion of participants with complete EQ-5D data. A small number of trial participants (n = 10) allocated to the control arm were erroneously enrolled into FNP. Following the ITT principle, they were analysed in their allocated arm regardless. Data were considered missing or incomplete when women did not complete the EQ-5D or provided a partially completed questionnaire. Two points would support the missing at random assumption used as the basis for the base-case analysis: (1) the missing data followed an intermittent pattern (eg, in both groups, more women were observed at 12 mo than at 6 mo, and the same pattern is observed at 18 and 24 mo); hence, CC assessment would be, as a minimum, inefficient because it would discard observed data from individuals with some missing outcomes; and (2) the BB data showed that participants with lower EQ-5D at baseline were more likely to have missing QALY data, which in turn suggests that the data are unlikely to be MCAR. 
| Health outcomes and QALYs
Despite any difference seen in the EQ-5D-3L across the groups, this translates to very little difference in utilities ( Figure 1) and QALYs between the FNP and usual care groups.
| Resource use and costs
There were no clear differences in resource use across the 2 groups (Table 3) , although A&E attendances for mothers and babies were somewhat higher in the FNP group. Babies in the usual care group had on average longer inpatient length of stay in hospital than those babies whose mothers were randomised to the FNP intervention.
Cost differences were very small across groups (Table 4) 
| Cost-effectiveness analysis
The incremental analysis (Table 5) a The complete dataset used for the base-case analysis comprised all mothers whose all six EQ-5D-3L assessments and all costs (GP records, health visitor/midwife visits, and hospital attendances) were available.
FIGURE 1
Mean EQ-5D scores at baseline and follow-up assessments up to 2 years following child birth the NICE currently accepted threshold of £20 000 to £30 000 per additional QALY (Figure 2 ).
The sensitivity analyses ( Table 5 ), showed that the conclusions from the base case analysis were robust to all scenarios, FNP remained a non-cost-effective intervention, with the incremental cost-effectiveness ratios much higher than the thresholds that NICE normally consider for reimbursement decisions. Because it was felt that the cost of the intervention is the main cost driver for the analysis, 
| DISCUSSION
This economic evaluation provides evidence that FNP is more costly than usual care and provides only a very small QALY gain. Similarly, the analysis of uncertainty confirmed that it is unlikely that FNP represents an efficient intervention even if the cost was substantially reduced.
The base case results indicate that the probability of FNP being costeffective is 17%, with the results being robust to sensitivity analyses.
There is evidence of positive results of the FNP intervention in the United States, a context where mothers are not able to access many statutory supportive health and social services, and maternity community-based services. In contrast, pregnant women in the United Kingdom can access a wide provision of maternal care including community care family doctors, midwives, and public health nurses, and as we observed in our trial sites, specialist teenage pregnancy midwives as well. It is worth it to note that the differences between the United States and United Kingdom health systems can explain the lack of clinical or quality-of-life benefits for those women who receive the FNP programme as a public service offered in the United Kingdom.
The BB trial is the first UK-based trial of FNP; therefore, this analysis represents the most up-to-date estimate of the cost-effectiveness of FNP when delivered in a universal, publicly funded, health care setting.
There are 2 noteworthy limitations of this study. The first limitation relates to the level of missing data. Despite steps to minimize missing data (eg, computer assisted telephone interviews), the number of EQ-5D questionnaires completed for each data collection wave decreased over time. This is a common problem in trial-based economic evaluations that is amplified where there are frequent assessments, as in here. It is worth noting that the use of HES data helped to minimize considerably the problem of incomplete data thus enabling more accurate estimates of hospital costs. The second limitation relates to the duration of the BB trial. In our trial, we are able to assess programme cost-effectiveness in the short-term only and we recognize that for preventative programmes benefits may be expected to accrue over a longer time period and in domains of child development.
Reported analyses of programme cost-effectiveness in the United
States have highlighted the advantage for high-risk families in particular over longer but variable periods. The Social Research Unit at Dartington, and Aldaba Limited conducted a cost-benefit analysis for FNP in the United Kingdom using a modelling approach that describes the longer-term savings by the FNP programme, indicating that key savings being related to higher earnings and higher attainment test scores 27 There have been some shortcomings identified with the economics analyses previously reported, 28 for example, some double counting of nonindependent outcomes. In one meta-analytic review, the cost savings for the programme were greatest for outcomes related to the mother (eg, reduced crime, higher earnings, and reduction in welfare) rather than the child. 29 Positive programme outcomes identified the trial include maternally reported child language Abbreviations: Sensitivity analysis i, CC according to ITT; Sensitivity analysis ii, MI removing midwife visits for FNP group; Sensitivity analysis iii, MI including mandatory withdrawals data; Sensitivity analysis iv, MI using self-report data; Sensitivity analysis v, MI halving the cost for FNP intervention.
*Difference between groups (Intervention -Control) and 95% confidence intervals using seemingly unrelated regression. The covariates used for the model were somoking status, language and gestation.
development. This is of potential longer-term importance but requires further evaluation over the medium term to first verify with objective ratings and second to determine whether any short-term advantage is continued to improvements in later outcomes such as school readiness. These objectives are currently being assessed in a linked study.
Besides, it could be argued that we only look at QoL for the women and not the children. The EuroQol Group has developed a child-friendly EQ-5D version (EQ-5D-Y) 30 ; however, the age of 8 is the lower age limit for which the instrument is valid; hence, the EQ-5D-Y was not applicable for the children in the BB trial. Regarding mothers, the EQ-5D-3L did detect differences in scores between stages of pregnancy (eg, women reported more problems in pain/discomfort and mobility at late pregnancy than any other follow-up point), which shows that this instru- England from removing the FNP programme would be around £21 million.
| CONCLUSION
The BB trial is the first UK-based trial of FNP. As discussed, the FNP intervention did not deliver significant benefits on any of the primary outcomes and only limited benefits on a small number of secondary outcomes where the risk of a chance finding is greater. Thus, taken together with the effectiveness findings, the results of this economic evaluation suggest that FNP does not represent a cost-effective intervention when adding FNP to existing services already offered to young pregnant women in England. However, it is important to note that these results are based on the 2-year trial only and cannot account for any longitudinal outcomes that may emerge at a later stage. Hence, at this time, we cannot recommend the continuation of FNP delivery and it may be the case that displacing the resources currently used in the FNP and investing in alternative interventions could potentially result in greater gains in child health, development, and family economic stability for this population.
